Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 295

recruiting
3 982
countries
28
conditions
2 106

3 662 trials match your criteria

Endometrial cancer

Not recruiting

Study on GEN1046 and Pembrolizumab for Patients with Advanced Endometrial Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:GEN1046

Study on the Safety and Effectiveness of MK-1308A, Pembrolizumab, and Lenvatinib for Patients with Advanced Liver Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib

Study of UCART22 for Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Alemtuzumab

Study of Pembrolizumab and Lenvatinib with TACE for Patients with Incurable Non-metastatic Liver Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib

Study on the Safety and Effects of ABBV-916 and MK-6240 for Patients with Early Alzheimer's Disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Florquinitau (18F)

Tourette's disorder

Not recruiting

Study on the Long-Term Safety of Ecopipam Hydrochloride Tablets for Children, Adolescents, and Adults with Tourette's Disorder

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ecopipam Hydrochloride

Study on Milvexian and Drug Combination for Patients Recovering from a Heart Attack

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid

Type 2 diabetes mellitus+3

Not recruiting

Evaluating Once Daily Orforglipron (LY3502970) Compared to Insulin Glargine in Adults with Type 2 Diabetes and Obesity or Overweight who Have Increased Cardiovascular Risk

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Canagliflozin

Study on Volixibat for Treating Itching in Patients with Primary Biliary Cholangitis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Volixibat

Study of Durvalumab and Tremelimumab for Patients with Advanced Liver Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab

Study on Ravulizumab for Children with Paroxysmal Nocturnal Hemoglobinuria or Atypical Hemolytic Uremic Syndrome

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Ravulizumab

Ewing's sarcoma+1

Not recruiting

Study of Regorafenib with Chemotherapy for Newly Diagnosed Patients with Metastatic Ewing Sarcoma

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Regorafenib
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.